Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Shirts BH;Shirts BH; Rodgers GM; Smock KJ
  • Source:
    Thrombosis research [Thromb Res] 2012 Sep; Vol. 130 (3), pp. e134-8. Date of Electronic Publication: 2012 Apr 28.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Pergamon Press Country of Publication: United States NLM ID: 0326377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2472 (Electronic) Linking ISSN: 00493848 NLM ISO Abbreviation: Thromb Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: Elmsford, N. Y., Pergamon Press.
    • Subject Terms:
      Partial Thromboplastin Time* ; Prothrombin Time*; Anticoagulants/*blood ; Mutation/*genetics ; Prothrombin/*genetics; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Reproducibility of Results ; Sensitivity and Specificity ; United States ; Young Adult
    • Abstract:
      Introduction: Prothrombin G20210A (PT20210) carriers have increased prothrombin levels and increased risk for venous thrombosis. We hypothesized PT20210 carriers would have decreased PT, aPTT, and dRVVT clotting times.
      Methods: We reviewed 1186 thrombotic risk panels that included PT, aPTT, dRVVT, and PT20210 genotype with potential confounding variables, excluding samples consistent with anticoagulant therapy or lupus anticoagulant presence. We examined relationships of PT20210 with PT, aPTT, and dRVVT correcting for covariates using multivariate regression. We confirmed associations in 1876 separate panel results and a group of homozygotes for PT20210 and used general linear models to determine if associated tests predict PT20210 status.
      Results: Neither PT, aPTT, nor dRVVT was shorter in PT20210 carriers. Contrary to our hypothesis, PT20210 was significantly associated with higher dRVVT (p=0.001), but not PT or aPTT. dRVVT differences were significant in a replicate sample p=0.035 and an additional sample of PT20210 homozygotes (p=0.02). Of all variables available, only dRVVT predicted PT20210 carrier status (p=0.0008, AUC=0.64).
      Conclusions: We observed an association between longer dRVVT and the prothrombin G20210A mutation in a retrospective observational study. These findings merit further study in large well-characterized clinical cohorts and laboratory research experiments.
      (Copyright © 2012 Elsevier Ltd. All rights reserved.)
    • Accession Number:
      0 (Anticoagulants)
      9001-26-7 (Prothrombin)
    • Publication Date:
      Date Created: 20120501 Date Completed: 20130131 Latest Revision: 20120821
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.thromres.2012.04.002
    • Accession Number:
      22542363